MPTP treatment in a type 2 diabetes (T2D) model increases raises the levels of α-synOs in both pancreas and midbrain, resulting in IL-1β secretion via NLRP3 activation, and ultimately exacerbates the loss of DA neurons (Wang et al., 2014). This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.